Paper Details

  1. Home
  2. Paper Details

Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer.

Author: BrownPowel H, ContrerasAlejandro, DimondEileen, Heckman-StoddardBrandy M, HernandezMike, KhanSeema A, LeeJ Jack, LiuDiane D, MaysCarrie, MuzzioMiguel, PatelAnisha B, PerloffMarjorie, SepedaValerie, ThomasParijatham S, VornikLana A, WeberDiane

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This phase I study evaluates topical bexarotene, a rexinoid with potential chemoprevention activity, for safety and toxicity in high-risk women for breast cancer.
Paper Details　
Original Abstract of the Article :
Bexarotene is a rexinoid that has been shown to prevent mammary tumors in mouse models but oral dosing has toxicities. This phase I s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/36228112

データ提供：米国国立医学図書館（NLM）

Topical Bexarotene: A New Hope for Breast Cancer Prevention

In the field of [oncology], developing effective chemoprevention strategies for breast cancer is a significant challenge. This study evaluates the safety and toxicity of topical bexarotene, a rexinoid with potential chemoprevention properties, in women at high risk for breast cancer. The study used a [phase I dose escalation study] design to assess the safety profile of topical bexarotene in a group of high-risk women. The results indicate that topical bexarotene is well tolerated, with no major safety concerns, suggesting its potential as a chemoprevention agent.

A New Frontier in Breast Cancer Prevention

The study's findings provide a promising avenue for breast cancer prevention. The safety and tolerability of topical bexarotene offer a potential alternative to oral bexarotene, which can have significant side effects.

A Ray of Hope in the Desert of Cancer

This study offers a glimmer of hope in the battle against breast cancer. It's like discovering a hidden oasis in the desert of cancer research, providing a potentially safer and more effective way to prevent the disease.

Dr.Camel's Conclusion

This study provides promising results for the development of topical bexarotene as a chemoprevention agent for breast cancer. It's a testament to the ongoing quest for new and innovative approaches to prevent this devastating disease.
Date :
  1. Date Completed 2023-01-10
  2. Date Revised 2023-08-04
Further Info :

Pubmed ID

36228112

DOI: Digital Object Identifier

NIHMS1844040

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.